Latest stories on NNVC
NanoViricides says Phase IIa trial of NV-387 in ebola ‘progressing well’
The Fly63 · neutralproduct/pr
NanoViricides says NV-387 demonstrates ‘strong’ parameters in animal model study
The Fly63 · neutralproduct/pr
NanoViricides announces Phase IIA Ebola trial of NV-387 is progressing well
The Fly63 · neutralproduct/pr
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
StockTitan63 · neutralproduct/pr
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
StockTitan55 · neutralgeneral
NanoViricides says Phase II trial of NV-387 in ebola ‘proceeding as designed’
The Fly55 · neutralproduct/pr
NANOVIRICIDES, INC. (NNVC) files 8-K
SEC 8-K50 · neutralgeneral
NanoViricides ‘actively exploring’ additional required funding
The Fly42 · neutralgeneral
NanoViricides reports FY26 EPS (41c) vs. (63c) last year
The Fly56 · neutralearnings
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
StockTitan56 · neutralproduct/pr
NanoViricides says Phase II trial of NV-387 in ebola starts enrollment, dosing
The Fly59 · neutralproduct/pr
NanoViricides begins Phase II trial of NV-387 in Monkeypox in DRC
The Fly59 · neutralproduct/pr
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
StockTitan59 · neutralproduct/pr
NanoViricides to begin Phase II trial of NV-387 in ebola next week
The Fly59 · neutralproduct/pr
NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus
The Fly59 · neutralproduct/pr
NanoViricides provides updateon Measles Drug Treatment Program
The Fly55 · neutralproduct/pr
NanoViricides registers to sell 2.52M shares of common stock for holders
The Fly28 · bearishgeneral
NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’
The Fly63 · neutralproduct/pr